BIO BB Biotech AG

EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share

EQS-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share

19.03.2025 / 17:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Media release of March 19, 2025

Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share

All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today.

Shareholders voted in favor of the proposal to pay out a dividend of CHF 1.80 gross per share. Payment will be made on March 25, 2025, the record date is March 24, 2025 and the ex-dividend date is March 21, 2025.

Shareholders re-elected the previous board members Dr. Thomas von Planta (Chairman), Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang, Prof. Dr. Mads Krogsgaard Thomsen and Camilla Soenderby for another one-year term of office.


For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, tel. 0

Head Investment Management Team BB Biotech
Dr. Christian Koch

Investor Relations

Claude Mikkelsen,

Media Relations
Tanja Chicherio,

 

 

Company profile  
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.



19.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: 5
E-mail:
Internet:
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 2103154

 
End of News EQS News Service

2103154  19.03.2025 CET/CEST

EN
19/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BB Biotech AG

 PRESS RELEASE

EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all pro...

EQS-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share 19.03.2025 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Media release of March 19, 2025 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted i...

 PRESS RELEASE

EQS-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträg...

EQS-News: BB BIOTECH AG / Schlagwort(e): Hauptversammlung/Dividende Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 1.80 pro Aktie 19.03.2025 / 17:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 19. März 2025 Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 1.80 pro Aktie An der ordentlichen Generalversammlung der BB Biotech AG von heute haben die Aktionäre sämtliche Anträge des Verwaltungsrats angenomm...

BB Biotech AG: 1 director

A director at BB Biotech AG bought 1,112 shares at 36.775CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

EQS-News: Geschäftsbericht 2024: BB Biotech positioniert sich in einem...

EQS-News: BB BIOTECH AG / Schlagwort(e): Jahresbericht Geschäftsbericht 2024: BB Biotech positioniert sich in einem herausfordernden Markt mit ersten Erholungstendenzen 21.02.2025 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 21. Februar 2025 Geschäftsbericht 2024: BB Biotech positioniert sich in einem herausfordernden Markt mit ersten Erholungstendenzen Im 4. Quartal setzte eine strukturelle Erholung im Biotechsektor ein, getrieben durch das wiedererstarkte Anlegerinteresse an klinischen Daten, Zulas...

 PRESS RELEASE

EQS-News: Annual Report 2024: BB Biotech positions for structural sect...

EQS-News: BB BIOTECH AG / Key word(s): Annual Report Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 21.02.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at February 21, 2025 Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 2024, especially the fourth quarter, signaled the early stage of a structural recovery in biotech, driven by renewed investor focus on clinical data, regulatory approvals, and commer...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch